Brief: Antengene Gets Ind Approval For Phase I Stamina-001 Study To Evaluate Atg-037 In China
02/11/2022 14:52
Nov 2 (Reuters) - Antengene Corporation Ltd 6996.HK :
* IND APPROVAL FOR PHASE I STAMINA-001 STUDY TO EVALUATE
ATG-037
IN CHINA
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106